Breast Cancer
The detection of genetic aberrations in solid tumors with DNA Fluorescence in situ Hybridization (FISH) probe technology is a powerful means to diagnose and more efficiently treat a wide range of cancers. Vysis® offers a comprehensive line of direct labeled DNA probes for solid tumor assessment. Single and multi-color probe sets offer researchers and clinicians a variety of ways to identify chromosome or locus deletions, gains, or translocations that have been associated with specific types of solid tumors. These probes can be applied to a variety of sample types prepared for metaphase or interphase analysis.
LandingSingleMenu not defined
- PathVysion®
- Breast Aneusomy Multi-Color Probe
- LSI C-MYC (8q24.12-q24.13) SpectrumOrangeTM Probe
- LSI Cyclin D1 (11q13) SpectrumOrange / CEP® 11 SpectrumGreenTM Probe
- LSI EGFR SpectrumOrange / CEP 7 SpectrumGreen Probe
- LSI TOP2A SpectrumOrange / CEP 17 SpectrumGreen Probe
- LSI TOP2A SpectrumOrange/ HER-2 SpectrumGreen/ CEP 17 SpectrumAqua Probe
- LSI ZNF217 (20q13.2) SpectrumOrange Probe
The Vysis probes for oncology, cytology, and pathology provide the following advantages:- Specific high-intensity signals without amplification and detection steps
- Low background for easy analysis
- Rapid, convenient, and easy-to-use assays
- Many probes designed for gene amplification detection include internal control probes
- Protocols that offer hybridization as quickly as four hours on the HYBriteTM Denaturation and Hybridization System
- Solid tumor probes have been optimized for paraffin-embedded tissues
